This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

ORBITA-2

  • Research type

    Research Study

  • Full title

    ORBITA-2: A placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina

  • IRAS ID

    242451

  • Contact name

    Alexandra Nowbar

  • Contact email

    alexandra.nowbar09@imperial.ac.uk

  • Sponsor organisation

    Joint Research Compliance Office, Imperial College London

  • Duration of Study in the UK

    3 years, 0 months, 1 days

  • Research summary

    Narrowing of the coronary arteries can cause chest pain on physical activitiy. This is called angina. Angioplasty of the narrowings is often carried out to relieve this. In the first blinded placebo-controlled trial of this therapy (ORBITA) we found that symptoms were no better than with intensive medical therapy (tablets). In this study we will determine how much difference angioplasty makes to symptoms without background medical therapy using the same scientific blinding of the patient and subsequent healthcare staff. Patients with single and multivessel coronary disease will be eligible. After the 12 week blinded phase, all patients will be unblinded and patients who had undergone placebo will be offered the active therapy.

  • REC name

    London - Central Research Ethics Committee

  • REC reference

    18/LO/1203

  • Date of REC Opinion

    31 Aug 2018

  • REC opinion

    Further Information Favourable Opinion